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Abstract
Background: Disease-modifying therapies benefit individuals with relapsing forms of multiple sclero-
sis, but their utility remains unclear for those without relapses.
Objective: To determine disease-modifying therapy use and costs in 2009, compare use in 2009 and
2000, and examine compliance with evidence-based guidelines.
Methods:We determined the extent and characteristics of disease-modifying therapy use by participants
in the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka) in 2000 (n¼2156) and 2009 (n¼2361)
and estimated out-of-pocket and total (payer) costs for 2009. Two multivariable logistic regressions
predicted disease-modifying therapy use.
Results: Disease-modifying therapy use increased from 55.3% in 2000 to 61.5% in 2009. In 2009,
disease-modifying therapy use was reported by 76.5% of participants with relapsing-remitting multiple
sclerosis, 73.2% with progressive-relapsing multiple sclerosis, 62.5% with secondary progressive mul-
tiple sclerosis, and 41.8% with primary progressive multiple sclerosis. Use was significantly associated
with relapsing-remitting multiple sclerosis, shorter duration of illness, one to two relapses per year, non-
ambulatory symptoms, using a cane, younger age, higher family income, and having health insurance.
Average annual costs in 2009 were US$939–3101 for patients and US$16,302–18,928 for payers.
Conclusion: Use rates were highest for individuals with relapsing-remitting multiple sclerosis, but
substantial for those with progressive courses although clinical trials have not demonstrated significant
benefits for them.
Keywords: Multiple sclerosis, disease-modifying therapies, utilization, cost
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Introduction
For over two decades, disease-modifying therapies
(DMTs) have transformed treatment for relapsing
forms of multiple sclerosis (MS). Clinical trials
involving individuals with secondary progressive
MS show reductions in relapse rates but, with few
exceptions,1 not in disability progression.2–6 In spite
of their increasing prevalence as the MS population
ages,7 we know little about the efficacy of DMTs in
older, non-ambulatory individuals because they are
generally excluded from clinical trials.
The US Food and Drug Administration indicates and
experts recommend DMTs for relapsing-remitting
MS and secondary progressive disease with continu-
ing relapses. In 2002, the American Academy of
Neurology’s (AAN) clinical practice guideline addi-
tionally stated that the ‘effectiveness [of interferon
beta] . . . [in secondary progressive MS] without
relapses is uncertain . . . [and although glatiramer
acetate [may be] helpful [in progressive disease],
there is no convincing evidence to support this
hypothesis.’2 The Paris Workshop Group took the
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same position.8 Shortly thereafter, echoing the Royal
College of Physicians of London,9 the National
Multiple Sclerosis Society (NMSS) stated that ‘it is
the consensus of researchers and clinicians [that
DMTs] can reduce future disease activity and
improve quality of life for many individuals with
relapsing forms of MS, including . . . secondary pro-
gressive disease [with] relapses.’10 In 2007, they
strengthened ‘can reduce’ to ‘are likely to reduce’.11
As early as 2002, MS experts registered concern
about DMT use in patients without active disease:
Vollmer and colleagues finding 28% of patients
with primary progressive MS taking DMTs, despite
the lack of data supporting such use, commented that
‘some treatment patterns . . . do not appear to be
rational given studies and consensus guidelines for
use of [DMTs].’12 Nevertheless, by 2004, use in this
population had increased by 20–40%.13
Without evidence to guide them, clinicians remain
divided on whether to initiate DMTs for individuals
with secondary progressive MS without relapses or
continue treatment started for relapsing-remitting
MS after relapses have ceased.14–17 Faced with
side effects and increasing prices, patients and fam-
ilies remain unsure about the costs versus benefits.
Given these complexities, we asked: ‘What are the
extent and predictors of DMT use in a representative
sample of individuals with MS?’ and ‘What are con-
sumer out-of-pocket (OOP) and total (payer) DMT
costs?’ Using data from the Sonya Slifka
Longitudinal Multiple Sclerosis Study (Slifka),18,19
we hypothesized that real-world DMT prescribing
practices would diverge from evidence-based guide-
lines and that use would be associated with income
and health insurance status. Although this is a health
services and not a clinical or treatment study, it
raises the most fundamental question clinicians,
patients, and families should ask themselves: ‘Is
DMT appropriate?’
Materials and methods
Data source
Initiated and funded by the NMSS, the Slifka Study
collected data from 2000 to 2010. We recruited
cohort 1 (N=2156) in 2000 and cohort 2 in 2007/
2008 (N¼ 2478) by randomly selecting participants
from the NMSS mailing lists and conducting nation-
wide outreach for under-represented groups, i.e.,
recently diagnosed (within 12 months), ages 18–24
years, African-American, and Hispanic. We stratified
by census region and rural and urban location, and
used fractional sampling intervals to select systematic
samples.18 We confirmed diagnoses with participants’
MS care providers or used proxy criteria (ever used a
DMT and can report diagnosis date, course, and three
typical MS symptoms). Comparison of cohort 1 to
MS respondents in the National Health Interview
Survey and the general population in the US Census
demonstrated that participants generally represented
the known demographic characteristics of the MS
population. For the 2009 interview, we recruited all
remaining cohort 1 and 2 participants achieving
response rates of 62.5% and 41.4%, respectively,
and a final sample of 2361.
We obtained institutional review board approval
with waiver of written informed consent for commu-
nity residents. At baseline, community residents pro-
vided verbal consent and nursing home residents
signed written consent forms.
The Slifka computer-assisted telephone interviews
used well-tested questions from federal surveys for
sociodemographic characteristics; standard defini-
tions of MS course, relapse, and progression;20 and
Disease Steps21 for disability status. At the end of
their 2007/2008 interviews, we asked participants to
keep daily records of their use of and spending on
medications and health services for complete and
accurate reporting during their 2009 interviews:
84% reported doing so or having so little to report
that recall was accurate. The ‘recall periods’
between individual participants’ 2007/2008 and
2009 interviews ranged from 13 to 27 months. We
adjusted each participant’s recall period to a stan-
dardized 12-month interval to obtain comparable
data on relapses, months of DMT use, and number
of prescriptions, i.e., number of relapses/months/pre-
scriptions*(12 months number of months in
recall period).
We report utilization and costs for five of the six
DMTs available in 2009: interferon beta-1a
(AvonexV
R
), interferon beta-1b (BetaseronV
R
), glatir-
amer acetate (CopaxoneV
R
), interferon beta-1a
(RebifV
R
), and natalizumab (TysabriV
R
). We excluded
mitoxantrone (NovantroneV
R
) because there were
only 21 users.
Estimating costs
To determine the average annual OOP cost, we mul-
tiplied participants’ reported payments per prescrip-
tion (standardized to a one-month supply) by the
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number of prescriptions or months of use if missing
(adjusted for variation in recall periods).
Determining the average annual total cost to private
and other payers is difficult because this information
is not publicly available. However, Medicaid pro-
grams release retail transaction data for drugs,
including quantities and total amounts paid to the
pharmacy from any source. In 2009, Medicaid med-
ication costs were similar to those of other payers
because their reimbursements used comparable dis-
counts off published list prices.22 We therefore esti-
mated the average annual total cost for each DMT by
multiplying the number of prescriptions or months of
use over patients’ adjusted recall periods by the
average price per prescription in the national
Medicaid drug utilization files.23
Data analysis
We used data from the 2009 interview to determine
the extent of DMT use overall and by drug, OOP and
total costs, and significant differences in demograph-
ic and disease characteristics between users and non-
users (chi-squared tests). We identified predictors of
DMT use and tested our hypothesis regarding the
impact of income and health insurance status using
two multivariable logistic regressions: model 1 with
only disease characteristics and model 2 with addi-
tional sociodemographic attributes and insurance
status. We report adjusted odds ratios (95% confi-
dence intervals) and use P values less than 0.05 for
statistical significance. Finally, for 2009, we show
how total and OOP costs compared by course.
Analyses excluded missing data, generally less
than 1% of responses.
To explore our hypothesis regarding the impact of
evidence-based guidelines on real-world DMT prac-
tice, we used previously published data from the
2000 Slifka interview.19 We compared the percentage
of individuals using DMTs in 2000 and 2009 by dis-
ease characteristics and age ([number users/number in
subsample]*100), calculated changes in use rates from
2000 to 2009, and assessed whether user characteristics
were consistent with evidence-based guidelines.
Results
DMT use
Seventy per cent of participants in 2009 (n=1651)
reported DMT use. Of these, 38.8% used glatiramer
acetate, 28.7% interferon beta-1a (AvonexVR ), 18.2%
interferon beta-1b, 17.9% interferon beta-1a
(RebifV
R
), and 11.9% natalizumab. Eighty-six per
cent of users (n=1417) took one DMT, with the
remainder using two (n=212), three (n=21) or four
(n=1) different DMTs over their recall periods. Of
the one DMT users, 82.7% (n=1172) reported con-
tinuous use throughout their recall periods; others had
complex patterns of starts, stops, and switches.
Tables 1 and 2 show participants’ demographic and
disease characteristics. DMT use fell with increasing
age from 93.8% of individuals aged 18–34 years to
28.8% of those aged 75 years and older (P<0.0001)
(Table 1). Use was also associated with being mar-
ried or never married compared to widowed or
divorced, being employed, having higher family
income (all P<0.0001), and being a student
(P=0.005). Having health insurance (P<0.0017)
and private health insurance (P<0.0001) were asso-
ciated with DMT use as was living in the northeast
census region (P=0.05).
Table 2 shows DMT use during standardized recall
periods by disease characteristics. Use rates differed
significantly across all categories (P<0.0001).
Among individuals with relapsing-remitting MS,
76.5% reported DMT use, compared with 41.8%
with primary progressive MS. Use rates fell from
87.5% of individuals diagnosed within five years
to 49.4% of those diagnosed 20 or more years ear-
lier. Among those using wheelchairs or scooters,
45.7% used a DMT, as did half of those completely
bedridden.
Comparing demographic and disease characteristics
of DMT users in 2000 and 2009 shows for 2009
higher percentages of individuals who were aged
55 years and older, African-American, married, wid-
owed, unemployed, needed a cane or bilateral sup-
port, and had postgraduate education and long
durations of illness (see Supplementary Table 1).
Table 3 shows the multivariable models predicting
DMT use. Adding sociodemographic characteristics
(model 2) did not substantially change the adjusted
odds ratios of use associated with disease character-
istics (model 1). Participants with relapsing-remitting
MS, non-ambulatory symptoms (e.g. sensory and
bladder problems, fatigue), one to two relapses per
year, shorter disease durations, or who needed a
cane were significantly more likely to use DMTs
than others. Significant sociodemographic character-
istics associated with DMT use were aged less than
45 years and family income of US$100,000 or great-
er. Having health insurance increased the probability
of use as did private coverage.
Minden et al.
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Table 1. Demographic characteristics associated with use of disease-modifying therapies (DMTs) during
recall period (September 2007 to November 2009).a
Sampleb
(n¼ 2359)
Any use
(n¼ 1651)
(70.0% of sample)
No use
(n¼ 708)
(30.0% of sample)
Characteristics n (%) n (%) n (%) P valuec
Gender 0.25
Men 495 (21.0) 336 (67.9) 159 (32.1)
Women 1864 (79.0) 1315 (70.5) 549 (29.5)
Age, years <0.0001
18–34 129 (5.5) 121 (93.8) 8 (6.2)
35–44 354 (15.0) 296 (83.6) 58 (16.4)
45–54 698 (29.6) 531 (76.1) 167 (23.9)
55–64 804 (34.1) 543 (67.5) 261 (32.5)
65–74 312 (13.2) 141 (45.2) 171 (54.8)
75þ 59 (2.5) 17 (28.8) 42 (71.2)
Race 0.37
White 2057 (88.2) 1430 (69.5) 627 (30.5)
African-American 172 (7.4) 129 (75.0) 43 (25.0)
Other 44 (1.9) 33 (75.0) 11 (25.0)
Multiple races 60 (2.6) 40 (66.7) 20 (33.3)
Ethnicity 0.05
Non-Hispanic 2232 (94.8) 1554 (69.6) 678 (30.4)
Hispanic 122 (5.2) 95 (77.9) 27 (22.1)
Marital status <0.0001
Married/living together 1673 (71.0) 1194 (71.4) 479 (28.6)
Widowed 123 (5.2) 61 (49.6) 62 (50.4)
Divorced/separated 318 (13.5) 215 (67.6) 103 (32.4)
Never married 244 (10.3) 180 (73.8) 64 (26.2)
Education 0.10
High school graduate or less 417 (17.7) 282 (67.6) 135 (32.4)
Some college/nursing degree 739 (31.4) 499 (67.5) 240 (32.5)
College graduate 683 (29.0) 491 (71.9) 192 (28.1)
Post graduate 518 (22.0) 377 (72.8) 141 (27.2)
Employment status <0.0001
Employed 928 (39.3) 710 (76.5) 218 (23.5)
Unemployed 1431 (60.7) 941 (65.8) 490 (34.2)
Student status 0.005
Student 101 (4.3) 83 (82.2) 18 (17.8)
Not a student 2258 (95.7) 1568 (69.4) 690 (30.6)
Family income, US$d <0.0001
<25,000 369 (16.9) 238 (64.5) 131 (35.5)
25,000–<50,000 483 (22.1) 314 (65.0) 169 (35.0)
50,000–<75,000 444 (20.3) 301 (67.8) 143 (32.2)
75,000–<100,000 331 (15.2) 242 (73.1) 89 (26.9)
100,000þ 557 (25.5) 434 (77.9) 123 (22.1)
Census region 0.05
Northeast 588 (24.9) 436 (74.1) 152 (25.9)
Midwest 654 (27.7) 442 (67.6) 212 (32.4)
South 585 (24.8) 412 (70.4) 173 (29.6)
West 532 (22.6) 361 (67.9) 171 (32.1)
(continued)
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DMT costs
Table 4 shows that in 2009, across the DMTs, the
average monthly total price per prescription ranged
from US$2056 to US$2536. For DMTs available in
2000, these prices ranged from US$781 to US$948. In
2009, average annual total costs per participant ranged
from US$16,302 to US$18,928 with large standard
deviations and ranges indicating high variability
across individuals and costs as high as US$56,483.
Average OOP costs ranged from US$130 to US$319
per prescription and US$939–3101 per year, with high
variability and payments up to US$7495. Costs do not
vary much by disease course, but do so within courses
(Table 5). Forty-eight per cent of natalizumab users
and 13.6–21.5% of other users had no OOP costs,
mainly because of full coverage by their insurance,
the Veteran’s Health Administration or state or other
programs (see Table 6).
Change in DMT use: 2000–2009
DMT use by Slifka participants rose from 55.3% in
200019 to 61.5% in 2009 (Table 7), primarily among
those with relapsing courses (relapsing-remitting MS
by 5.2% and progressive-relapsing MS by 19.5%
for a total of 24.7%). Use also rose for individuals
aged over 54 years (by 15.8%) and those with long
durations (by 20.7% for six to 15 years and 14.9%
for over 16 years). Rates increased by 4.3% for
individuals with secondary progressive MS, but
decreased by 2.1% for those with primary progres-
sive MS.
Discussion
Utilization of DMTs by Slifka Study participants
between 2000 and 2009 indicate a clear and
persistent deviation from readily available
scientific evidence. Even though higher use rates
in 2009 for relapsing-remitting MS show conformity
to evidence-based guidelines, and increased use
from 2000 to 2009 for both relapsing courses sug-
gests effective guideline dissemination, for other
patients many prescribers seem to have paid
little heed to the recommendations or were not
Table 1. Continued
Sampleb
(n¼ 2359)
Any use
(n¼ 1651)
(70.0% of sample)
No use
(n¼ 708)
(30.0% of sample)
Characteristics n (%) n (%) n (%) P valuec
Urban/rural status 0.24
Urban 1939 (82.2) 1367 (70.5) 572 (29.5)
Rural 420 (17.8) 284 (67.6) 136 (32.4)
Insurance status during recall period 0.0017
Insured entire time 2258 (95.7) 1583 (70.1) 675 (29.9)
Insured some of the time 69 (2.9) 54 (78.3) 15 (21.7)
Uninsured entire time 32 (1.4) 14 (43.8) 18 (56.3)
Health insurance typee <0.0001
Private only 1214 (51.5) 944 (77.8) 270 (22.2)
Medicare only 164 (7.0) 102 (62.2) 62 (37.8)
Other public only 173 (7.3) 112 (64.7) 61 (35.3)
Mixed coverage 749 (31.8) 457 (61.0) 292 (39.0)
Uninsured 55 (2.3) 32 (58.2) 23 (41.8)
aDemographic characteristics reflect status at the time of interview (end of recall period) except for health insurance
status. DMT use covers the entire recall period.
bStudy sample n=2361. Two participants were excluded from analyses because of missing data.
cChi-squared tests. Statistically significant P<0.05.
dTotal combined income before taxes of all family members and from all sources during previous calendar year,
including money from jobs, net income from business, farm or rent, pensions, dividends, interest, social security,
retirement income, disability insurance, unemployment payments, public assistance, etc.
eHealth insurance types: ‘Private only’ includes commercial, Tricare, American Association of Retired Persons, drug
plans; ‘Other public only’ includes any public insurance except Medicare, i.e. Medicaid, General Medical Assistance,
Veterans Health Administration, Indian Health Service, Workers Compensation, other government plan; ‘Mixed
coverage’ includes any combination of private plus public insurance.
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educated in appropriate implementation. Despite the
absence of data showing benefit for individuals with
non-relapsing forms of MS presented in clinical
guidelines carefully formulated by teams of
experts, over one-third of participants with
primary progressive MS and about one-half with
secondary progressive MS received a DMT.
Similarly, without evidence of benefit for more dis-
abled and older individuals, over one-third of
participants requiring a wheeled mobility aid used
DMTs and use increased by nearly 16% among
individuals over the age of 54 years, the median
onset for secondary progressive disease.24 We
cannot tell from these data whether older individuals
Table 2. Disease characteristics associated with use of disease-modifying therapies (DMTs) during recall
period (September 2007 to November 2009).a
Sampleb
(n¼ 2359)
Any use
(n¼ 1651)
(70.0% of sample)
No use
(n¼ 708)
(30.0% of sample)
Characteristics n (%) n (%) n (%) P valuec
Course <0.0001
Relapsing-remitting 1523 (65.3) 1165 (76.5) 358 (23.5)
Secondary progressive 528 (22.6) 330 (62.5) 198 (37.5)
Primary progressive 201 (8.6) 84 (41.8) 117 (58.2)
Progressive-relapsing 82 (3.5) 60 (73.2) 22 (26.8)
Duration since diagnosis, years <0.0001
1–5 447 (19.0) 391 (87.5) 56 (12.5)
6–10 565 (24.0) 472 (83.5) 93 (16.5)
11–15 373 (15.8) 277 (74.3) 96 (25.7)
16–20 349 (14.8) 202 (57.9) 147 (42.1)
20þ 624 (26.5) 308 (49.4) 316 (50.6)
Relapses in past yeard <0.0001
0 1440 (62.1) 943 (65.5) 497 (34.5)
1 445 (19.2) 348 (78.2) 97 (21.8)
2 312 (13.5) 253 (81.1) 59 (18.9)
3–4 93 (4.0) 63 (67.7) 30 (32.3)
5þ 28 (1.2) 17 (60.7) 11 (39.3)
Disability statuse <0.0001
No MS symptoms 241 (10.2) 152 (63.1) 89 (36.9)
Mild MS symptoms with no
limitations on activity or lifestyle
369 (15.6) 274 (74.3) 95 (25.7)
Non-ambulatory symptoms 556 (23.6) 437 (78.6) 119 (21.4)
Trouble walking but no aid used 192 (8.1) 146 (76.0) 46 (24.0)
Can walk 25 feet without a cane 234 (9.9) 176 (75.2) 58 (24.8)
Cannot walk 25 feet without a cane 289 (12.3) 206 (71.3) 83 (28.7)
Cannot walk 25 feet without
bilateral support
188 (8.0) 127 (67.6) 61 (32.4)
Requires wheelchair or scooter 282 (12.0) 129 (45.7) 153 (54.3)
Completely bedridden 8 (0.3) 4 (50.0) 4 (50.0)
aDisease characteristics reflect status at the time of interview (end of recall period). DMT use covers the entire
recall period.
bStudy sample n=2361. Two participants were excluded from analyses because of missing data.
cChi-squared test. Statistically significant P<0.05.
dStandardized to a 12-month recall period.
eSource: Hohol et al.21 Based on free text responses from previous waves of Slifka study interviews, ‘no MS
symptoms’ and ‘completely bedridden’ were added. ‘Non-ambulatory symptoms’ include ‘sensory abnormalities’,
‘bladder impairment’, ‘incoordination’, ‘weakness’, or ‘fatigue’ of any severity.
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Table 3. Adjusted odds ratios from multivariable logistic regression models predicting use of disease-modifying therapies (DMTs)
(September 2007 to November 2009).a
Model 1 Model 2
Predictor variables AOR (P value)b Odds ratio (95% CI) AOR (P value)b Odds ratio (95% CI)
Course (reference group relapsing-remitting)
Secondary progressive 0.75 (0.05) 0.58–0.98 0.73 (0.05) 0.55–0.97
Primary progressive 0.32 (0.0001) 0.22–0.46 0.38 (0.0001) 0.25–0.56
Progressive-relapsing 1.19 0.67–2.09 1.03 0.57–1.86
Duration since diagnosis, years (reference group 1–5 years)
6–10 0.78 0.54–1.12 0.77 0.52–1.14
11–15 0.44 (0.0001) 0.30–0.64 0.51 (0.01) 0.34–0.77
16–20 0.21 (0.0001) 0.15–0.31 0.24 (0.0001) 0.16–0.36
20þ 0.16 (0.0001) 0.11–0.22 0.23 (0.0001) 0.16–0.35
Relapses in past yearc (reference group zero)
1 1.47 (0.01) 1.12–1.92 1.51 (0.01) 1.13–2.01
2 1.56 (0.01) 1.12–2.17 1.69 (0.01) 1.19–2.39
3þ 0.69 0.45–1.06 0.78 0.50–1.23
Disability statusd (reference group no or mild MS symptoms)
Non-ambulatory symptoms 1.47 (0.01) 1.12–1.95 1.48 (0.01) 1.10–1.99
Occasional or regular use of cane 1.77 (0.001) 1.32–2.37 1.82 (0.001) 1.31–2.52
Requires bilateral support, wheelchair,
scooter, or bedridden
1.18 0.86–1.61 1.21 0.85–1.73
Gender (reference group men)
Women 0.96 0.74–1.23
Age, years (reference group <45)
45–54 0.74 0.52–1.05
55–64 0.64 (0.05) 0.45–0.91
65þ 0.32 (0.0001) 0.21–0.48
Race (reference group white)
Non-white 0.89 0.64–1.24
Ethnicity (reference group non-Hispanic)
Hispanic 1.48 0.84–2.60
Education (reference group less than college graduate)
College graduate or more 1.04 0.83–1.30
Employment status (reference group unemployed)
Employed 0.82 0.63–1.05
Family incomee (reference group< $50,000)
US$50,000–99,999 1.11 0.86–1.43
US$100,000þ 1.51 (0.01) 1.11–2.07
Health insurancef (reference group private only)
All other types 0.94 0.71–1.24
Uninsured 0.46 ( 0.05) 0.24–0.89
aDisease and demographic characteristics reflect status at the time of interview (end of recall period). DMT use covers the entire recall period.
bStatistically significant P<0.05.
cStandardized to a 12-month interval.
dSource: Hohol et al.21 Based on free text responses from previous waves of Slifka study interviews, ‘no MS symptoms’ and ‘completely
bedridden’ were added. ‘Non-ambulatory symptoms’ include ‘sensory abnormalities’, ‘bladder impairment’, ‘incoordination’, ‘weakness’, or
‘fatigue’ of any severity.
eTotal combined income before taxes of all family members and from all sources during previous calendar year, including money from jobs,
net income from business, farm or rent, pensions, dividends, interest, social security, retirement income, disability insurance, unemployment
payments, public assistance, etc.
fHealth insurance types: ‘Private only’ includes commercial, Tricare, American Association of Retired Persons, drug plans; ‘Other public only’
includes any public insurance except Medicare, i.e. Medicaid, General Medical Assistance, Veterans Health Administration, Indian Health
Service, Workers Compensation, other government plan; ‘Mixed coverage’ includes any combination of private plus public insurance.
AOR: adjusted odds ratio; CI: confidence interval.
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with long disease durations and progressive dis-
abling courses were continuing therapy started
when younger, less disabled, and still having relap-
ses, or whether treatment was initiated more recent-
ly. However, given evidence of declining DMT
persistence among patients with longer duration
and greater disability, our results are likely to reflect
non-evidence-based initiation of DMT.25
For medicine as a whole, non-adherence to evi-
dence-based guidelines varies widely from 10% to
80%,26,27 and many explanations have been pro-
posed. Unintentional deviations may reflect lack of
knowledge, error, or uncritical reliance on others’
opinions (‘herding’ behavior).28 Intentional devia-
tions, often valid, include contraindications, patient
and physician preferences, absent or ambiguous
cost-benefit data, and patient demographics.26
In 2000 and certainly in 2009, there was repeated
clinical trial evidence that DMTs do not work ade-
quately in non-relapsing MS. Still, without positive
evidence from purposefully designed clinical trials,
there is controversy and uncertainty for clinicians
and patients looking for guidance on treatment deci-
sions. In 2013, the AAN advised clinicians to ‘not
Table 4. Total and out-of-pocket costs for users of disease-modifying therapies (DMTs) during
recall period.a
Interferon
beta-1a
(AvonexV
R
)
(n¼ 474)
Interferon
beta 1-b
(BetaseronV
R
)
(n¼ 301)
Glatiramer
acetate
(CopaxoneV
R
)
(n¼ 641)
Interferon
beta-1a
(RebifV
R
)
(n¼ 296)
Natalizumab
(TysabriV
R
)
(n¼ 196)
Number of months usedb
Mean (SD)
Median
Range
10.4 (3.3)
12
1–12
10.0 (3.5)
12
1–12
9.9 (3.6)
12
1–12
9.3 (3.9)
12
1–12
8.4 (4.0)
9.8
1–12
Total price per prescription,c US$
2339 2403 2536 2353 2056
Total cost per year,d US$
Mean (SD)
Median
Range
18,718 (9780)
23,612
1080–28,074
17,338 (10,207)
14,994
1109–28,834
18,928 (10,867)
18,727
1127–30,431
17,503 (10,446)
18,075
1086–56,483
16,302 (8272)
18,132
914–24,669
OOP coste per purchase, US$
Mean (SD)
Median
Range
133 (489)
40
2–6960
154 (532)
50
1–5400
130 (411)
35
1–4325
150 (574)
50
2–7000
319 (1008)
50
5–7500
OOP cost per year,e US$
Mean (SD)
Median
Range
939 (3109)
272
6–33,600
1,041 (3442)
326
4–28,800
952 (3852)
240
3–49,200
1,088 (4347)
300
1–48,000
3,101 (11,692)
360
3–90,000
Participants with zero OOP costs, n (%)
102 (21.5%) 41 (13.6%) 104 (16.2%) 50 (16.9%) 94 (48.0%)
aTotal cost is the amount paid by both insurers and patients to the pharmacy. Out-of-pocket (OOP) cost is the patient
component of the total cost. Rebates and coupons are not accounted for due to data limitations. Costs are given in 2009
US dollars.
bStandardized to a 12-month interval.
cPrice per prescription¼ amount paid by both insurers and patients to the pharmacy per prescription estimated from
2009 State Drug Utilization Data. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/
index.html. Accessed October 25, 2018. Prices per prescription in 2000 are available for interferon beta-1a (AvonexV
R
)
(US$784), interferon beta 1-b (BetaseronV
R
) (US$948), and glatiramer acetate (CopaxoneV
R
) (US$781).
dTotal cost per year¼ price per prescription number of prescriptions per year (or months of use if number of
prescriptions missing).
eOOP cost per prescription and OOP cost per year¼ patient component of the applicable total costs. Excludes
participants who paid zero.
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prescribe [DMTs] to patients with disability from
progressive, nonrelapsing forms of MS’ because
there was no evidence of benefit that outweighed
potential adverse effects and financial burden, par-
ticularly for those over aged 54 years and no longer
ambulatory.14 Implicit in this statement is the
requirement of adequate evidence for a treatment
recommendation and a recommendation to follow
published guidelines.
Other MS experts responded that this was ‘an over-
simplified recommendation’ because ‘progressive
patients who are on one of these agents and
having no relapses are likely obtaining a partial
treatment benefit and should remain on the
agent’.29 Implicit in this statement are two argu-
ments. First, the ‘absence of evidence is not evi-
dence of absence’,30 i.e., lacking evidence of
benefit does not mean there is no benefit, simply
that more research is needed. Second, patients
cannot wait until we have the data. The ‘absence
of evidence’ argument may justify treatment when
outcomes are truly unknown, but when well-
designed randomized clinical trials have been neg-
ative, the argument should be that further studies
are required.
Table 5. Comparison of total and out-of-pocket costs per year by disease course for disease-modifying therapies (DMTs) during
recall period (September 2007 to November 2009).a,b
Total cost OOP cost
RRMS SPMS PPMS PRMS RRMS SPMS PPMS PRMS
Mean (SD), US$ 20,999
(9502)
20,048
(9427)
19,707
(9367)
19,168
(10,494)
1,073
(4815)
963
(3897)
589
(1434)
824
(2567)
Median, US$ 26,327 23,363 22,320 23,436 261 173 187 152
Range, US$ 987–58,505 1170–56,483 2808–30,431 914–30,431 0–90,000 0–49,200 0–9684 0–17,465
aTotal cost is the amount paid by both insurers and patients to the pharmacy. Out-of-pocket cost is the patient component of the total cost.
Rebates and coupons are not accounted for due to data limitations. Costs are given in 2009 US dollars.
bNumber of users by course: RRMS¼1165, SPMS¼330, PPMS¼84, PRMS¼60.
Percentage of users in course: RRMS¼76.5%, SPMS¼62.5%, PPMS¼41.8%, PRMS¼73.2%.
Percentage of users in sample: RRMS¼49.3%, SPMS¼14.0%, PPMS¼3.6%, PRMS¼2.5%.
OOP: out-of-pocket; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary
progressive multiple sclerosis; PRMS: progressive-relapsing multiple sclerosis.
Table 6. Reasons for zero out-of-pocket costs for users of disease modifying therapies (DMTs) during recall period.
Interferon
beta-1a
(AvonexV
R
)
(n¼474)
Interferon
beta 1-b
(BetaseronV
R
)
(n¼301)
Glatiramer
acetate
(CopaxoneV
R
)
(n¼641)
Interferon
beta-1a
(RebifV
R
)
(n¼296)
Natalizumab
(TysabriV
R
)
(n¼196)
n (%) n (%) n (%) n (%) n (%)
Participants reporting zero OOP costsa 102 (21.5) 41 (13.6) 104 (16.2) 50 (16.9) 94 (48.0)
Reasons reported for zero OOP costsb
Insurance, Veterans Health Administration,
state or other public program
66 (65.4) 35 (85.4) 58 (59.8) 34 (72.3) 71 (76.3)
Pharmaceutical company program 23 (22.8) 2 (4.9) 17 (17.5) 8 (17.0) 5 (5.4)
Other (received during hospital stay, purchased
before recall period, free sample,
Chronic Disease Fund or National Organization
for Rare Diseases)
12 (11.9) 4 (9.8) 22 (22.7) 5 (10.6) 17 (18.3)
aFor percentages, denominators are the number of users of the particular DMT.
bFor percentages, denominators are the number of participants who provided reasons (101, 41, 97, 47, 93, respectively, from left to right).
OOP: out-of-pocket.
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Fortunately, a randomized clinical trial is underway
on the safety of discontinuing DMTs in individuals
aged 55 years and older without relapses or MRI
changes, but data will not be available until at
least 2021.31 Meanwhile, the field wants to know
‘What can we do now?’ First, patients and clinicians
can read the latest guidelines32 and research,33–38
discuss reasons for departures, and reach a shared
decision despite the discomfort of having little
clear and compelling evidence. Second, the MS
community can engage in ‘unbiased discussion’39,40
that examines the full range of issues from patient
and family preferences to societal costs due to
increased healthcare expenditures, taking care not
Table 7. Comparison of use of disease-modifying therapies (DMTs) by Slifka study participants at the time
of their interviews in 2000 and 2009.a
Rates of use, %b
Change in
percentage pointsCharacteristics 2000c 2009
Sample 55.3 (1193/2156) 61.5 (1451/2361) þ6.2
Course
Relapsing-remitting MS 63.5 (834/1314) 68.7 (1048/1525) þ5.2
Secondary progressive MSd 47.2 (220/466) 51.5 (272/528) þ4.3
Primary progressive MSe 36.4 (90/247) 34.3 (69/201) –2.1
Progressive-relapsing MS 42.7 (38/89) 62.2 (51/82) þ19.5
Duration since diagnosis, years
<5 75.5 (627/830) 75.7 (340/449) þ0.2
6–15 50.6 (408/807) 71.3 (669/938) þ20.7
>16 30.4 (158/519) 45.3 (441/973) þ14.9
Disability statusf
No MS symptoms NA 55.0 (133/242) NA
Mild MS symptoms with no
limitations on activity on lifestyle
58.6 (259/442) 67.2 (248/369) þ8.6
Non-ambulatory symptoms 60.9 (349/573) 71.6 (399/557) þ10.7
Trouble walking but no aid used 58.4 (136/233) 67.2 (129/192) þ8.8
Can walk 25 feet without a cane 61.9 (122/197) 65.0 (152/234) þ3.1
Cannot walk 25 feet without a cane 55.0 (169/307) 60.6 (175/289) þ5.6
Cannot walk 25 feet without
bilateral support
49.6 (61/123) 58.5 (110/188) þ8.9
Requires wheelchair or scooter 34.8 (94/270) 35.8 (101/282) þ1.0
Completely bedridden 0.0 (0/7) 50.0 (4/8) þ50.0
Age, years
18–54 63.6 (959/1509) 70.8 (837/1183) þ7.2
>54 36.3 (234/644) 52.1 (612/1175) þ15.8
a2000 analyses: DMTs include interferon beta-1a (AvonexV
R
), interferon beta-1b (BetaseronV
R
), glatiramer acetate
(CopaxoneV
R
). 2009 analyses: DMTs include the above plus interferon beta-1a (RebifV
R
), natalizumab (TysabriV
R
).
Denominators do not exclude two subjects with missing data (as in Table 2).
bUnweighted percentage of users in sample or subgroup (number of users/number in sample or subgroup). Numerators
are the number of users at time of interview (not over recall period as in Table 2).
cSource: Minden et al.19
dOf the 528 patients in 2009 who reported a course of secondary progressive MS, 333 (63.1%) reported zero relapses
and 195 (36.9%) reported one or more relapses in the preceding year.
eOf the 201 patients in 2009 who reported a course of primary progressive MS, 39 (19.4%) reported one or more
relapses in the preceding year.
fSource: Hohol et al.21 Based on free text responses from previous waves of Slifka study interviews, ‘no MS
symptoms’ and ‘completely bedridden’ were added. ‘Non-ambulatory symptoms’ include ‘sensory abnormalities’,
‘bladder impairment’, ‘incoordination’, ‘weakness’, or ‘fatigue’ of any severity.
NA: category not included in 2000 interview.
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to present opinion as fact and to recognize the com-
munal context28 and external influences on treatment
decisions. The 2018 guideline development process
is noteworthy for its inclusion of people with MS
and public reviews and emphasis on patient-doctor
communication: as such, it sets an example for dis-
cussing its recommendation that ‘clinicians should
assess the likelihood of future relapse’ and ‘may
advise discontinuation of DMT in people with [sec-
ondary progressive MS] who do not have ongoing
relapses (or . . . MRI activity) and have not been
ambulatory . . . for at least 2 years.32
Our study showed that annual total costs for first
generation DMTs were three times higher in 2009
than in 2000. They have skyrocketed since then to
over US$60,000,41,42 some even to US$86,000,43
with annual increases seven times higher than aver-
age drug inflation.44 We do not know, but should
ask, whether use without evidence was contributory
to the cost containment efforts discussed below.
Escalating total costs inevitably increases the
patient’s share: even in 2009 some individuals
reported extraordinary OOP spending.
Our observation that people with high incomes and
health insurance were more likely to use DMTs
almost certainly indicates that low income and inad-
equate coverage limited access to these medications,
reflecting well-known causes of healthcare disparity.
Even though expansion of Medicaid with the
Affordable Care Act provides coverage to many pre-
viously uninsured patients, their DMT utilization is
lower than among the commercially insured.45 Use
is also lower among those with high cost-
sharing plans.46
Limitations
This study has limitations. First, the data do not
include DMTs approved since 2009. However, a
fundamental concern has not changed since 2000:
in spite of clear and consistent guidelines, and no
new evidence to the contrary, many patients are
still newly prescribed or continued on DMTs without
evidence of their effectiveness. Furthermore, from
2009 to 2014, injectable DMTs were still used by
93.7% of almost 9000 individuals with MS initiating
and 60.6% of those switching DMTs.47
Second, Slifka participants may not fully represent
individuals with MS in the USA. Nevertheless, the
sample includes patients receiving care in both aca-
demic and community settings and from MS special-
ists, general neurologists, and primary care
physicians, thereby representing the full range of
treatment practices. Because we followed partici-
pants over a critical nine-year period, from early
adoption to established DMT use, we could show
that prescribing DMTs for patients for whom there
was no evidence of benefit continued in spite of
consistent evidence-based guidelines.
Third, because information on private sector drug
prices is unavailable, we had to rely on Medicaid
payments to impute total DMT costs for patients
mainly covered by private insurance and, without
rebate information, we may have overestimated by
an unknown amount. Still, Medicaid is the best avail-
able source of retail transaction costs, particularly for
the years of our study. Because OOP costs were based
on participants’ daily records, they are reliable.
Despite these limitations, our results have important
implications for the present and for future studies of
DMT utilization. Our findings can serve as bench-
marks as prices rise and payers intensify efforts to
control costs, producing ‘a cascade of negative
effects’ on patients and families.44 A recent survey
of 59 health plans revealed that 93% require prior
authorization and 58% use step therapy for
DMTs,48 and formulary restrictions have been
shown to affect adherence negatively.49 The overuti-
lization of DMTs by patients unlikely to benefit will
heighten insurers’ cost concerns and could lead to
greater constraints on patient and clinician preferen-
ces. If patient-centered care is to become a certainty,
decisions about DMT use ought to be driven by the
evidence and further informed by the clinician’s med-
ical judgment and the patient’s goals and values. Our
data indicate that real-life decision-making is highly
variable and that more evidence and education are
needed to ensure the most appropriate treatments for
the right individuals at the right time at the right cost.
Improving MS health outcomes and access to care
while controlling escalating costs will require con-
certed efforts to adhere to the evidence-based guide-
lines we have now, while continually working to
improve them,26 study their implementation and
acceptance, and remove barriers to prompt DMT
initiation and equitable use. Guideline dissemination
and education are essential, and should be free of
pharmaceutical and payer influence.
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